Table 2. HIVDR in the Mwanza cohort.
| Age (years) | Sample number | NRT RAM | NNRTI RAM | PI RAM | Affected drug (low-level resistance) | Affected drug (high-level resistance) | TDM | time since HIV test (years) |
| 20.5 | TZ.09.032647 | A98G1 | NVP | neg. | 0.31 | |||
| 25.4 | TZ.08.029746 | D30N | ATV | NFV | neg. | 0.58 | ||
| 26.4 | TZ.08.017184 | M41L | D4T, AZT, ddI, ABC | neg. | 1.05 | |||
| 28.0 | TZ.08.014495 | M184I | ABC | 3TC, FTC | EFV | 0.33 | ||
| 30.2 | TZ.08.022112 | M184I | G190E | ABC | 3TC, FTC, NVP, EFV | neg. | 8.3 | |
| 32.2 | TZ.09.001336 | G73S | SQV, NFV, ATV | neg. | 0.28 | |||
| 32.4 | TZ.09.001332 | M184I | K103N | ABC | 3TC, NVP, EFV, DLV | neg. | 0.18 | |
| 33.2 | TZ.08.017176 | M41L | D4T, AZT, ddI, ABC | NVP | 2.50 | |||
| 33.7 | TZ.08.023280 | V75A | D4T, ddI | neg. | 1.63 | |||
| 36.7 | TZ.08.017197 | T215I | K103N | V82T | D4T, AZT, ddI, ABC, SQV/r, LPV/r, ATV, NFV | NVP, EFV, DLV | n.d. | 2.81 |
| 38.7 | TZ.09.001323 | G190E | G73S | SQV/r, NFV,ATV, DLV | NVP, EFV | neg. | 1.06 | |
| 42.6 | TZ.09.006017 | V82A | LPV/r, SQV/r, ATV, NFV | neg. | 4.60 | |||
| 44.9 | TZ.10.002035 | T69N2 | ddI | negative | 1.14 | |||
| 46.7 | TZ.08.017195 | K103N | NVP, EFV, DLV | n.d. | 0.38 | |||
| 46.8 | TZ.10.003309 | E44D3V118I3 | 3TC | neg. | 0.15 | |||
| 51.4 | TZ.08.017193 | Y188H | NVP, EFV, DLV | neg. | 0.04 |
RAM according to the Stanford HIV Drug Resistance Database [17] in 16/88 baseline samples. Mutations associated with a score of 60 were attributed as high-level resistance-associated mutations (RAM) and mutations with a score of 10–35 were attributed as low-level RAM. Mutations listed for WHO HIVDR surveillance [18] are indicated in bold. Superscripted numbers identify the reasons for excluding the respected mutations from the HIVDR list: 1) nonpolymorphic, but at highly polymorphic position; 2) polymorphic position in subtypes B, F, CRF01_AE; 3) polymorphic in multiple subtypes. ABC: Abacavir; ATV: Atazanavir; AZT: Zidovudine; ddI: Didanosine; DLV: Delaviridine; D4T: Stavudine; EFV: Efavirenz; FTC: Emtricitabine; LPV: Lopinavir; NFV: Nelfinavir; NVP: Nevirapine; SQV: Saquinavir; 3TC:Lamivudine [29]. Underlined drugs are part of the local first line regimens, double line underlined drugs are part of local second line regimens. Data derived from 88 sequenced samples. Therapeutic drug monitoring (TDM) was performed from plasma samples collected at baseline for NNRTIs (Efavirenz and Nevirapine) and PIs (Nelfinavir, Saquinavir, Atazanavir and Lopinavir).